Objective-Familial hypercholesterolemia (FH) is characterized by an elevated low-density lipoprotein cholesterol and increased risk of premature coronary artery disease. However, the general picture and mutational spectrum of FH in China are far from recognized, representing a missed opportunity for the investigation. Approach and Results-A total of 8050 patients undergoing coronary angiography were enrolled. The diagnosis of clinical FH was made using Dutch Lipid Clinic Network criteria, and the information of relatives was obtained by inquiring for the probands or from their own medical records of certain clinics/hospitals. Molecular analysis of FH was performed using target exome sequencing in LDLR (low-density lipoprotein cholesterol receptor gene), APOB (apolipoprotein B gene), and PCSK9 (proprotein convertase subtilisin/kexin type 9 gene). As a result, 3.5% of the patients with definite/ probable FH phenotype (definite 1.0% and probable 2.5%) were identified. Women FH had fewer premature coronary artery disease (women <60, or men <55 years of age) when compared with men FH (70.6% versus 82.7%; P<0.001), whereas angiographic extension of coronary artery disease was significantly increased with FH diagnosis in both men and women (P<0.001). Patterns of medication use in definite/probable FH were as follows: nontreated, 20.6%; low intensity, 6.0%; moderate intensity, 68.3%; and high intensity, 5.0%. However, none of them had achieved the lowdensity lipoprotein cholesterol <100 mg/dL. Additionally, mutational analysis was performed in 245 definite/probable FH cases, and risk variants were identified in 115 patients, giving a detection rate of 46.9%. Conclusions-We showed firsthand a common identification but poor treatment of patients with FH phenotype in Chinese coronary angiography patients. Genetic data in our FH cases might contribute to update the frequency and spectrum of Chinese FH scenarios. 
F amilial hypercholesterolemia (FH) is a common genetic disorder of cholesterol metabolism affecting 1 of 200 to 500 subjects worldwide, and it is characterized by markedly elevated levels of low-density lipoprotein cholesterol (LDL-C) and increased risk for premature coronary artery disease (pCAD). [1] [2] [3] Individuals with the more severe homozygous form of FH develop clinically significant CAD, and if untreated, they rarely survive beyond the age of 30 years. Moreover, in those with the less severe heterozygous form, the onset of significant CAD is also generally earlier than that in the general population and presents a topic of extensive concern.
Too often, FH is diagnosed after the occurrence of a major coronary event, and the detected prevalence of FH varies among certain races as the gene founder effects. 4, 5 Hence, identification of the affected individuals prior to the onset of an atherosclerotic event is clearly warranted. Implementation of appropriate screening can make a huge effect on the prevention of CAD and related detrimental sequelae that benefit from the early detection, diagnosis, and treatment of FH. 6 Large-scale clinical studies of FH have been reported from many countries, 2, [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] but the features of FH in China are largely unknown. 17 Furthermore, the actual prevalence of FH is likely to be underestimated in the past, and the FH trait is masked by the CAD phenotype or more common risk factors without the genetically elevated cholesterol levels. 3 Hence, the aim of present study was to investigate patients with FH phenotype and further provide molecular data on mutations for patients with FH in the Division of Dyslipidemia of Fu Wai Hospital, the only national center of dyslipidemia in China.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Prevalence of FH
Basic characteristics of the study population are summarized in Table 1 . The mean (±SD) age of the participants was 57.2±10.5 years, of whom 68.7% were men and 83.8% were with CAD and 37.8% with pCAD (<55 years for men and <60 years for women). The mean total cholesterol and LDL-C were 165.25±50.58 and 101.54±43.63 mg/dL, respectively. In the sample, there were 1.0% definite FH, 2.5% probable FH (3.5% definite/probable FH), 18 .9% possible FH, and 77.6% unlikely FH.
Considering that patients with FH is often at high risk for the early onset of CAD but with heterogeneity depending on known or unknown factors, 18, 19 we have provided data on FH in patients with different CAD status. In a group of patients with pCAD (as defined above), 5.8% of the population had definite/probable FH, whereas in a group of patients with non-pCAD (CAD with onset age ≥55 years for men and ≥60 years for women), 1.1% of the population had definite/probable FH ( Table 2) .
The prevalence of FH was also evaluated according to the stratum of age ( Figure 1 ) and sex (Table 2 and Figure 1 ). There were 2.9% definite/probable FH in men undergoing coronary angiography (CAG), whereas women undergoing CAG had higher prevalence of FH (4.7%) than men. The prevalence of definite/ probable FH was significantly higher in patients aged ≤40 years (P<0.001) in both men (9.3%) and women (13.5%). Furthermore, 5.2% (7.6%) of the men (women) with pCAD had definite/probable FH, whereas in a group of patients with non-pCAD, 0.7% (2.1%) of the men (women) had definite/probable FH. Table 2; Table I in the online-only Data Supplement).
Coronary Features of FH
As shown in Figure 2 , the coronary severity assessed by the Gensini scoring system was significantly increased with the FH diagnosis in both men and women (medians of gensini score [GS] As mentioned above, the data also indicated that the values of GS were higher in FH men than in women in both crude and adjusted models, even considering those with pCAD. However, in patients with non-pCAD, we found that the GS was increased with FH diagnosis in men but not in women (medians of GS, men 30 versus 35 versus 41; women 25 versus 32 versus 28, respectively). Moreover, no matter the patients are with or without FH, the extent of coronary stenosis was higher in men than in women.
Cholesterol-Lowering Medications of FH
Three patterns of statin use (high-, moderate-, and low-intensity patterns) were defined on the basis of the statin type and potency as described previously. As shown in Table 3 , the most frequently received pattern at the admission was the moderateintensity medication with 53.5% of the population, followed by low-intensity medication with 14.6% of the population, and high-intensity medication with 0.8% of the population. When considering the patterns of medication according to the diagnosis of FH, we found the higher prevalence of taking high-and moderate-intensity but lower prevalence of taking low-intensity medication in patients with definite/probable FH or possible FH compared with those of unlikely FH. Remarkably, 31.0% of the population was untreated, of which, 84.7% (2115/2498) of the subjects were from the group of unlikely FH. The proportions of untreated subjects were 20.6% in definite/probable FH, 21.4% in possible FH, and 33.8% in unlikely FH.
The groups of possible and unlikely FH had the treated LDL-C levels elevated with the reduced grade of medications (Table 3 ). In the group of patients with definite/probable FH, however, the LDL-C levels from high to low were found in patients taking nontreatment and high-, low-, and moderateintensity medications (Table 3) . Additionally, women with definite/probable FH were of older age and had the higher untreated LDL-C levels than men with definite/probable FH ( Data shown are mean±SD or n (%). *Statistical significance. Apo indicates apolipoprotein; AS, atherosclerosis; BMI, body mass index; CAD, coronary artery disease; FH, familial hypercholesterolemia; HbA1C, hemoglobin A1C; HDL-C, high-density lipoprotein cholesterol; Hs-CRP, high-sensitivity C-reactive protein; LDL-C, low-density lipoprotein cholesterol; Lp(a), lipoprotein (a); TC, total cholesterol; and TG, triglyceride.
The Correlation of Classical Risk Factors With FH Diagnosis
Using multivariable regression analysis enrolling age, sex (male), body mass index, hypertension, diabetes mellitus, hypertriglyceridemia, low high-density lipoprotein, pre-revascularization, pre-acute myocardial infarction, smoking, cholesterol-lowering medication intensity, Lp(a), and hs-CRP in the model, we investigate the potential correlations with FH diagnosis in total population and in subgroups divided according to CAD status (pCAD, non-pCAD, and non-CAD; Table II in the online-only Data Supplement). As a result, we found that FH diagnosis was associated with young age and high levels of Lp(a) in total or in any subgroup; men was at lower risk compared with women for FH diagnosis in patients with pCAD or non-pCAD, but there was no difference in FH diagnosis between men and women in patients with non-CAD; hs-CRP presented the positive association with FH only in the patients with pCAD.
Genetic Mutations in Definite/Probable FH Cases
Of 281 definite/probable FH patients, 245 had well-preserved blood samples for DNA extraction. Therefore, a total of 245 cases were performed mutational analysis.
Of the 245 patients, we identified 125 patients with 172 mutations in LDLR (low-density lipoprotein cholesterol receptor gene; 111), APOB (apolipoprotein B gene; 53), and PCSK9 (proprotein convertase subtilisin/kexin type 9 gene; 9) using target next-generation sequencing (Figure 3 ). The majority of the variants (61.0%; n=105) in LDLR (90), APOB (11) , and PCSK9 (4) had been reported previously. From the remaining 67 variants that were identified for the first time in our population, 46 in LDLR (11), APOB (34), and PCSK9 (1) were predicted in silico analysis as a potential mutation (Table III in the online-only Data Supplement), 21 were classified as benign or tolerated mutations, and all the 46 potential mutations of target next-generation sequencing were validated by Sanger sequencing. As a result, 151 risk variants were observed in 115 patients, giving a positive Figure 2 . Associations of the FH probability with coronary severity assessed by gensini score system. CAD indicates coronary artery disease; FH, familial hypercholesterolemia; Non-pCAD, nonpremature coronary artery disease; and pCAD, premature coronary artery disease. Furthermore, the mutated patients had been divided into subgroups according to the number of genes involved (Figure 4) . We found that 85.6% (107/125) of the patients had monogenic mutations associated with FH. Of which, 68.2% (73/107) were found to have mutation in LDLR, 29.0% (31/107) in APOB, and 2.8% (3/107) in PCSK9. When only patients with the risk mutations (n=115) were considered, the monogenic-caused FH accounted for 88.7% (102/115), with 70.6% (72/102) in LDLR, 26.5% (27/102) in APOB, and 2.9% (3/102) in PCSK9, respectively. The mutations that were considered to be benign were counted as zero in the analysis. The remaining 13 patients were compounded in LDLR, APOB, and PCSK9, with 11 having mutations in both LDLR and APOB and 1 in PCSK9 and APOB, and 1 had all the 3 mutated. Importantly, we found that even in monogenic FH, there were 2 or 3 loci in the corresponding gene. For example, of the 102 patients with only 1 mutated gene, 18.6% had the compounded variants in each gene (19/102; 16 in LDLR and 3 in APOB).
The exons with mutated sites of the 3 genes are summarized in Figure 5 . The LDLR mutations in these patients commonly distributed in exon 12 (20.8%, 21/101), 4 (18.8%, 19/101), 9 (12.9%, 13/101), 3 (11.9%, 12/101), and 11 (10.9%, 11/101). The APOB mutations were found to be relative frequency in exon 26 (37.8%, 17/45), 25 (15.6%, 7/45), and 29 (13.3%, 6/45). The 5 PCSK9 mutations were observed in exon 2 (40%, 2/5), 9 (20%, 1/5), and 10 (40%, 2/5).
Additionally, in the present analysis, 130 patients did not present an identifiable risk mutation in any exon of LDLR, APOB, or PCSK9, including 10 patients with a predicted benign mutation. The lipid profile of the mutative-negative patients was compared with that of the mutation-positive patients. As shown in Table IV in the online-only Data Supplement, mutated patients had higher Dutch Lipid Clinic Network score, and the levels of total cholesterol, LDL-C, and apoB were higher than those of the mutative-negative patients (all P<0.001).
Discussion
This was the first study to address the clinical diagnosis of FH in Chinese patients undergoing CAG in hospital settings of the Division of Dyslipidemia, 17, 20 which might represent the general picture because of the patients hospitalized from across the country. The dyslipidemia and coronary care settings are useful environment for detecting patients likely to have FH, who should then be referred to a specialist service for confirmation of the diagnosis and management for the condition. What's more, we provided molecular data on mutations in LDLR, APOB, and PCSK9 in our definite/probable FH cases to map the genetic variations of Chinese patients with FH.
The findings of the present study suggested that the definite/probable FH phenotype may be encountered in 3.5% of the participants; a subgroup of patients with pCAD showed a frequency of 5.8%, and women aged ≤40 years presented the highest frequency of 13.5%. The common frequency of FH might be explained by the estimation methods and selected populations. 7 Moreover, recent studies from Do et al 21 showed that FH was responsible for ≈2% of myocardial infarction in people with age <60 years. Therefore, the present study, in accordance with the previous studies, 8, 11, 13 pointed out the importance of phenotypic assessment of FH in clinical settings. Additionally, we also recommended the need of a program for the screening of FH in high-risk clinical areas, for example, dyslipidemia unit, coronary or cardiothoracic care, which should be strongly recommended.
As shown in the present study and elsewhere, an important picture could still be found with the LDL-C levels in risk, underscoring a significant shortfall in the management of patients with FH. 3, [22] [23] [24] Previous studies have suggested among Chinese individuals with elevated LDL-C, the proportion of those who were aware, treated, or controlled for their condition was much lower than that in Western populations. 25 Current dyslipidemia guidelines of China still lack a separate section for FH and systematic recommendations for the diagnosis, detection, and treatment of FH. 26 The fact of poor awareness/management of FH might be explained by variables. [27] [28] [29] Of them, hospitals or cardiologists can play a significant role because they are likely to be the first to encounter the patients and their families, but the clinical care is not well developed and provided in China to date. Patients' knowledge and compliance are also reasons for great concern. Importantly, the high risk of CAD in patients with FH on medications showed in the present study might suggest that even in patients on medications, the dose of statin therapy was insufficient or poorly responsive, and the treatment was introduced or started too late in life, when their CAD had already developed. Other studies also support massive undertreatment of patients with FH. 3 Notably, we also found that the risk of CAD in patient on medication was higher than that in those off medication even in the same FH status, further highlighting an urgent importance of identification and intensive treatment for the highrisk patients as early as possible. Therefore, to improve the diagnosis and management of severe hypercholesterolemia, the government and health policymakers, special medical care units including our division, and patients can make great sense to provide coverage for routine FH clinical screening and make lipid-lowering medications affordable/considerable. We also found that patients with FH had markedly increased Lp(a) and hs-CRP levels compared with unlikely FH subjects. Furthermore, our study indicated that Lp(a) was independently associated with the diagnosis of FH, and the findings are consistent with previous reports. 30, 31 Recently, some investigators have suggested that the elevated Lp(a) may be an additional cause of the FH phenotype and, thus, pointing out the importance in measuring Lp(a) in patients with FH to identify those with the high concentrations or those at high CAD risk. 32 While hs-CRP was related significantly and independently to FH but only in patients with pCAD when considered in subgroups divided by CAD status. Additionally and interestingly, we found a sex difference in coronary stenosis of patients with FH, assessed by GS system. Similar to patients with non-FH, male patients with FH had severe coronary stenosis than female patients with FH in both patients with CAD and those with pCAD.
The Dutch Lipid Clinic Network criteria is the most commonly used diagnostic algorithm for clinical FH, and it produces scores that lead to classification of either definite or probable FH. The clinical criteria is critical to distinguish FH from conditions with phenotypical presentations to ensure appropriate therapeutic management and genetic test. Although genetic studies of FH has already been extensively studied all over the world, reports of FH mutations in the Chinese population are still limited. More recently, Chiou and Charng 33 reviewed the limited literatures recognized by genetic diagnosis of FH in Han Chinese. They found that the mutations of LDLR identified in China were less than those in the European populations, and the mutations of APOB were also common in Han Chinese population. 33 Moreover, the majority of the mutations reported in China had not been described in other ethnicities, highlighting a significant ethnic difference in mutations as causes of FH. 33 To date, an FH registry was complied only in Taiwan, and 2 small cohort studies with genetic diagnosis had been reported. 34, 35 The limited data in China, however, might reflect an urgent need for national screenings for FH in this population. In the present study, we first used target exon sequencing in FH cohort of mainland China and showed the spectrum of FH gene mutations. Specifically, our results supported LDLR mutations as the primary finding and the APOB and PCSK9 mutations as secondary and preliminary finding. Any mutations not already reported but predicted to be potential risk in silico analysis could not be considered pathogenic without family studies or functional testing at present.
Current guidelines on FH generally estimate that mutations in APOB comprise 5% to 10% of genetic FH, PCSK9 <3%, compared with 90% to 95% because of mutations in LDLR. 36 However, it is also well-recognized that FH is a condition of severe underdiagnosis regarding variable clinical diagnostic criteria currently used and absence of an independent code in the WHO international classification of disease to obtain a reliable estimates of FH. 3, 37 The APOB mutation carriers are found to have lower average LDL-C increase, leading to a further underrepresentation of APOB mutations carriers in several studies. 38 In the present study, we used the Dutch Lipid Clinic Network criteria with a comparatively comprehensive information included to identify patients with FH phenotype, and we, for the first time, performed the analysis from the patients in our division of dyslipidemia, which is the only national center of dyslipidemia in China with subjects from across the country. The observed elevated prevalence of APOB mutations (particularly the 34 specific mutations), in accordance with the report from Yang et al 34 showing that 18 out of 30 families were identified by harboring LDLR or APOB mutations with frequencies of 77.8% (14/18) and 22.2% (4/18), respectively, might indicate an important gene effect of APOB mutations on Chinese FH. Moreover, investigators from Taiwan and other ethnicities have suggested recently that the number of APOB mutations is increasing, 16, 36 most notably in Taiwan. 34, 38 The elevated prevalence of APOB mutations among Chinese patients might be possible, as pointed out by Andersen et al. 38 Additionally, most currently available genetic testing in APOB is focused on exon 26 and p.Arg3500Trp rather than on the entire coding region. 39 Of note, there are case studies reporting mutations in the non-hot spot of APOB. 40, 41 Therefore, it may be beneficial to undertake sequencing of the entire APOB gene because other rare variants in the gene may be responsible for the patient's clinical phenotype. 36, 39 In the present study, we screened the whole exons in APOB and found some mutations in nonhot region. The hot exon of 26 showed a frequency of 37.8% in APOB mutations. The significant contribution of APOB mutations and the spectrum of FH noted in the present study might provide important data for mainland Chinese. Further studies might be needed to confirm our results.
We also found that the FH phenotype was not often straightforward in relation to the FH genotype. The mutation-positive patients had higher LDL-C than mutation-negative patients, indicating that the patients with FH genotype might pay more attention in clinical management even under the fact of FH phenotype, with an elevated risk of events regardless of the genotype. 42 Additionally, the mutation-negative patients with FH phenotype might be in conditions as follows: (1) a polygenic form of hypercholesterolemia rather than a monogenic disorder of cholesterol metabolism; (2) defects in other genes associated with lipid disorder or even in an unknown gene without identification at present; (3) variants affecting known or unknown genes through an undescribed mechanism as an epigenetic phenomenon; and (4) environmental or acquired response instead of inheritance.
When interpreting the results of this study, several limitations need to be considered. First, we did not include the criteria relating to corneal arcus and molecular testing for FH diagnosis in the present study. However, we selected the patients with definite/probable FH for mutational analysis to map the genetic variants in FH. Our data also pointed to the need to actively seek index cases in high-risk population or in high-risk medical units and in first-degree family members of identified cases with FH. Second, we enrolled the patients undergoing CAG in a single center; although our division is the only national center of dyslipidemia unit in China, we cannot rule out the patients who were attracted or recommended since its reputation as a specific spot across the country, resulting in a highly selected cohort with an overvalued prevalence. Nevertheless, the present study might be recognized as a key opportunity for detecting FH embedded in routine clinical care, at least in dyslipidemia or coronary care unit. Further population-based studies with a larger sample from multicenter might be warranted in China. Third, although in silico analysis classified 46 of the 67 unreported mutations in LDLR, APOB, and PCSK9 as potential risk, we could not conclude these mutations as causal of FH at present, and each variant if defined as causal needs to undergo greater scrutiny. The analysis in the present study was performed as a tool for the prediction of being potential (probably damaging, deleterious, and disease-causing); further functional studies on these novel mutations are necessary to confirm their pathogenic effects and characterize the mutational complexity. Additionally, the LDL-C levels for FH diagnosis were the estimated values rather than the true untreated LDL-C for the medical-treated patients and might have certain bias. The increased levels of triglyceride and Lp(a) in FH might suggest that some patients could actually have combined disorder. The confounding factors, such as age, sex, diabetes mellitus, and so on might have certain impact on the phenotype of patients with FH.
In conclusion, FH phenotype was frequent among patients undergoing CAG in China. Also, the pCAD susceptibility and severity were more serious in FH. The high LDL-C levels irrespective of the intensity of medications reflected a great concern for the unawareness and undertreatment of FH. Genetic testing in patients with FH phenotype might improve the patients classification and clinical management. Taken together, the present study indicated firsthand an urgent need for early identification and management of FH in Chinese population.
